ライフサイエンスコーパス: systemic embolism

1 ke; p = 0.020, adjusted p = 0.023 for stroke/systemic embolism).

2 function is a potent predictor of stroke and systemic embolism.

3 The primary endpoint was stroke or systemic embolism.

4 ssociated with increased risk for stroke and systemic embolism.

5 bigatran 110 mg BID in preventing stroke and systemic embolism.

6 icantly increased risk of ischemic stroke or systemic embolism.

7 or the primary outcome of ischemic stroke or systemic embolism.

8 farin for the primary end point of stroke or systemic embolism.

9 to warfarin for the prevention of stroke or systemic embolism.

10 utcome was ischemic or hemorrhagic stroke or systemic embolism.

11 ndpoint of stroke, cardiovascular death, and systemic embolism.

12 including stroke, myocardial infarction, and systemic embolism.

13 f cardiac thrombus formation associated with systemic embolism.

14 dity and mortality due to related stroke and systemic embolism.

15 ctors of stroke/transient ischemic attack or systemic embolism.

16 rms of the risk of having an ischemic stroke/systemic embolism.

17 prior stroke, transient ischemic attack, or systemic embolism.

18 ned as stroke, transient ischemic attack, or systemic embolism.

19 been shown to reduce the risk of stroke and systemic embolism.

20 miodarone-treated patients had a stroke or a systemic embolism (1.58%/year vs. 1.19%/year; adjusted h

21 The incidence of stroke or systemic embolism (1.88% vs. 1.86%) and death (1.88% vs.

22 was associated with a higher rate of stroke/systemic embolism (13.6% vs. 3.2%, p = 0.021, p = 0.047

23 5%; RR, 0.89; 95% CI, 0.82-0.98), and stroke/systemic embolism (2.40% versus 3.13%; RR, 0.77; 95% CI,

24 was significantly associated with stroke or systemic embolism, adjusted hazard ratio 1.98 (1.42-2.78

25 ect of rivaroxaban and warfarin on stroke or systemic embolism among VKA-naive and VKA-experienced pa

26 The primary efficacy outcome was stroke or systemic embolism, analysed by intention to treat.

27 r of follow-up), the rate of ischemic stroke/systemic embolism and all-cause mortality (per 100 perso

28 The rate of ischemic stroke/systemic embolism and all-cause mortality (per 100 perso

29 The adjusted hazard ratio of ischemic stroke/systemic embolism and all-cause mortality was 0.55 (95%

30 For ischemic stroke/systemic embolism and for all-cause mortality, hazard ra

31 from 0.62 to 0.65 (p = 0.0009) for stroke or systemic embolism and from 0.59 to 0.69 for cardiac deat

32 Annualized event rates of stroke or systemic embolism and major bleeding and hazard ratios (

33 dysfunction have a higher risk of stroke or systemic embolism and major bleeding but show consistent

34 e clinical cohort, there were similar stroke/systemic embolism and major bleeding rates with dabigatr

35 ith the clinical outcomes of ischemic stroke/systemic embolism and major bleeding using univariate an

36 f apixaban vs warfarin on rates of stroke or systemic embolism and major bleeding were consistent in

37 F trial demonstrated similar risks of stroke/systemic embolism and major/nonmajor clinically relevant

38 outcomes, i.e., stroke (ischemic stroke and systemic embolism) and major bleeding in patients treate

39 mine whether the primary efficacy (stroke or systemic embolism) and safety (major bleeding and nonmaj

40 nial hemorrhage, the rate of ischemic stroke/systemic embolism, and all-cause mortality (per 100 pers

41 Efficacy outcomes were stroke or systemic embolism, and all-cause mortality.

42 therapy (warfarin) for prevention of stroke, systemic embolism, and cardiovascular death in nonvalvul

43 mpared to warfarin for prevention of stroke, systemic embolism, and cardiovascular death in patients

44 composite primary efficacy endpoint (stroke, systemic embolism, and cardiovascular death) is expresse

45 primary efficacy end point included stroke, systemic embolism, and cardiovascular death, and the pri

46 r preventing the combined outcome of stroke, systemic embolism, and cardiovascular death, as well as

47 mposite efficacy end point including stroke, systemic embolism, and cardiovascular/unexplained death,

48 ents of ischemic stroke, hemorrhagic stroke, systemic embolism, and cardiovascular/unexplained death.

49 rior stroke/transient ischemic attack, prior systemic embolism, and congestive heart failure were ass

50 statistics from 0.629 to 0.653 for stroke or systemic embolism, and from 0.591 to 0.731 for cardiac d

51 eeding; apixaban 5 mg B.I.D. reduced stroke, systemic embolism, and mortality as well as major bleedi

52 attack, Caucasian race, hypertension, prior systemic embolism, and New York Heart Association functi

53 Outcomes included the composite of stroke or systemic embolism, any stroke, and major bleeding among,

54 he population attributable risk of stroke or systemic embolism associated with subclinical atrial tac

55 We compared the rates of stroke/systemic embolism at 1 year according to diabetes status

56 was a significantly increased risk of stroke/systemic embolism at 1 year versus either no diabetes (5

57 The cumulative rate of stroke and stroke/systemic embolism at follow-up were 13.6% and 15.9%, res

58 pixaban compared with warfarin for stroke or systemic embolism, bleeding, and mortality appear simila

59 in statistically similar rates of stroke and systemic embolism, but apixaban had a lower risk of majo

60 was associated with a higher rate of stroke/systemic embolism, but not a higher mortality, at 30 day

61 The primary end point was stroke and systemic embolism by intention to treat.

62 was a significantly lower risk of stroke and systemic embolism (by 26%) for dabigatran (150 mg BID) c

63 arfarin therapy for the prevention of stroke/systemic embolism/cardiovascular death, there was a sign

64 superior to warfarin in preventing stroke or systemic embolism, caused less bleeding, and resulted in

65 ter than warfarin at prevention of stroke or systemic embolism, causes less bleeding, and results in

66 ive rivaroxaban had a reduction in stroke or systemic embolism compared with those taking warfarin (1

67 as associated with lower rates of stroke and systemic embolism compared with warfarin, without an inc

68 Rates of ischemic stroke/systemic embolism, death, and bleeding.

69 consistently reduced the rate of stroke and systemic embolism, death, and major bleeding compared wi

70 including stroke, non-central nervous system systemic embolism, death, myocardial infarction, and ble

71 terval [CI], 1.16-1.5) but similar stroke or systemic embolism event rates (HR, 1.09; 95% CI, 0.88-1.

72 rences, the long-term incidence of stroke or systemic embolism (hazard ratio [HR]: 1.38; 95% confiden

73 to 8.17; P<0.001) and of ischemic stroke or systemic embolism (hazard ratio, 2.49; 95% CI, 1.28 to 4

74 troke, nonfatal acute myocardial infarction, systemic embolism, heart failure development, or severe

75 these patients had higher rates of stroke or systemic embolism (HR, 1.47; 95% CI, 1.20-1.81) and majo

76 d to be more effective (outcome of stroke or systemic embolism: HR, 0.78; 95% CI, 0.67-0.91; vascular

77 n (HR, 1.53; 95% CI, 1.17-2.01 for stroke or systemic embolism; HR, 1.56; 95% CI, 1.27-1.93 for major

78 (13%), syncope or arrhythmia in 5 (10%), and systemic embolism in 3 (6%).

79 associated with the occurrence of stroke and systemic embolism in a large, international atrial fibri

80 ID reduced the primary outcome of stroke and systemic embolism in comparison with warfarin.

81 uperior to warfarin in preventing stroke and systemic embolism in nonvalvular atrial fibrillation, bu

82 erosis of the aorta is a potential source of systemic embolism in patients undergoing cardiac cathete

83 jor risk factor for perioperative stroke and systemic embolism in patients undergoing cardiac surgery

84 mpared with warfarin (n = 8657) on stroke or systemic embolism in patients with 1 dose-reduction crit

85 is non-inferior for prevention of stroke and systemic embolism in patients with atrial fibrillation a

86 to warfarin for the prevention of stroke and systemic embolism in patients with atrial fibrillation a

87 ulation therapy for the prevention of stroke/systemic embolism in patients with atrial fibrillation.

88 inferior to warfarin in preventing stroke or systemic embolism in patients with atrial fibrillation.

89 ive and safe for the prevention of stroke or systemic embolism in patients with atrial fibrillation.

90 antagonists for the prevention of stroke and systemic embolism in patients with atrial fibrillation.

91 nferior to warfarin in preventing stroke and systemic embolism in patients with atrial fibrillation.

92 all indications except for the prevention of systemic embolism in patients with mechanical heart valv

93 ion of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial F

94 ion of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial F

95 ion of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial F

96 y over warfarin for prevention of stroke and systemic embolism in the 150-mg dose and significantly l

97 dditional factors associated with stroke and systemic embolism included elevated diastolic blood pres

98 ted with reduced risk for ischemic stroke or systemic embolism, intracranial hemorrhage, and all-caus

99 found regarding risk for ischemic stroke or systemic embolism, intracranial hemorrhage, myocardial i

100 the primary endpoint of all-cause stroke or systemic embolism, ischaemic stroke, and all-cause morta

101 rall and cardiovascular mortality, stroke or systemic embolism, ischemic stroke, major and intracrani

102 Rates of stroke or systemic embolism, major bleeding, and all-cause mortali

103 Rates of stroke or systemic embolism, major bleeding, and mortality were co

104 The risks of stroke or systemic embolism, major bleeding, and mortality were hi

105 an compared with warfarin reduced stroke and systemic embolism, major bleeding, and mortality.

106 ed rates of myocardial infarction, stroke or systemic embolism, major bleeding, cause-specific hospit

107 ncidence of myocardial infarction, stroke or systemic embolism, major bleeding, hospitalization, or d

108 fied as "net clinical benefit" (all strokes, systemic embolism, MI, pulmonary embolism, major bleedin

109 Rates of stroke or systemic embolism, myocardial infarction, and bleeding w

110 an follow-up: 0.99 years) included stroke or systemic embolism, myocardial infarction, major bleeding

111 l effectiveness end point of ischemic stroke/systemic embolism, no significant differences of the NOA

112 During the 30 days postprocedure, stroke or systemic embolism occurred after 16/4624 (0.35%) procedu

113 All-cause stroke or systemic embolism occurred in 4 patients (2.3% per year)

114 While the effects of local and systemic embolism on plant water transport and physiolog

115 rence favoring novel oral anticoagulants for systemic embolism (OR, 0.84; 95% CI, 0.72-0.97; P=0.01),

116 ent TTR and the composite outcome of stroke, systemic embolism, or major hemorrhage.

117 e of SCAF in those with a history of stroke, systemic embolism, or transient ischemic attack was 39.4

118 comes were arterial thromboembolism (stroke, systemic embolism, or transient ischemic attack) and maj

119 ly decreased the risk for ischemic stroke or systemic embolism (p = 0.0004 and p = 0.0006, respective

120 statistic from 0.620 to 0.635 for stroke or systemic embolism (p = 0.0226), from 0.592 to 0.711 for

121 ary efficacy analysis was rates of stroke or systemic embolism (per 100 patient-years) by intention t

122 20 +/- 5 months, the rates of death, stroke, systemic embolism, pericardial effusion, and major bleed

123 Stroke or systemic embolism (primary outcome), major bleeding (saf

124 ing 1.9 years, the annual rates of stroke or systemic embolism ranged from 0.74% in the bottom NT-pro

125 9 years follow-up, annual rates of stroke or systemic embolism ranged from 0.76% in the lowest hs-TnI

126 9-year period, the annual rates of stroke or systemic embolism ranged from 0.87% in the lowest hs-TnT

127 Annual rates of stroke or systemic embolism ranged from 0.9% to 2.03% (P<0.001); o

128 ts who received amiodarone had a stroke or a systemic embolism rate of 1.24%/year versus 1.85%/year (

129 ho did not receive amiodarone, the stroke or systemic embolism rate was 1.29%/year versus 1.57%/year

130 Stroke and systemic embolism rates at 30 days were 0.8%, 0.3%, and

131 Stroke/systemic embolism rates during the at-risk period were s

132 In VKA-experienced patients, stroke and systemic embolism rates were 1.51%, 1.15%, and 1.74% per

133 In VKA-naive patients, stroke and systemic embolism rates were 1.57%, 1.07%, and 1.69% per

134 Stroke/systemic embolism rates were consistent among older (2.2

135 ated with significantly increased stroke and systemic embolism risk and a lower time in the therapeut

136 erior to well-managed warfarin for stroke or systemic embolism (S/SE) prevention and reduced bleeding

137 AC) or warfarin for prevention of stroke and systemic embolism (SE) in AF.

138 l enlargement (LAE) is a predictor of stroke/systemic embolism (SE) in atrial fibrillation (AF) patie

139 irst composite coprimary endpoint of stroke, systemic embolism (SE), or cardiovascular/unexplained de

140 mary efficacy endpoint (composite of stroke, systemic embolism [SE], and cardiovascular/unexplained d

141 strong, independent predictor of stroke and systemic embolism, second only to prior stroke or transi

142 We examined the risk of stroke or systemic embolism (SSE) conferred by heart failure (HF)

143 ffective as warfarin in preventing stroke or systemic embolism (the primary end point), because the p

144 The primary efficacy end point was stroke or systemic embolism; the safety end point we studied was m

145 ng the study that report all-cause stroke or systemic embolism, vascular death, myocardial infarction

146 revious stroke or TIA, the rate of stroke or systemic embolism was 1.01 per 100 patient-years of foll

147 revious stroke or TIA, the rate of stroke or systemic embolism was 2.46 per 100 patient-years of foll

148 Analysis of stroke or systemic embolism was based on intention to treat.

149 of rivaroxaban versus warfarin on stroke or systemic embolism was consistent: Rates per 100 patient-

150 (6 randomized controlled trials, n=30,699), systemic embolism was favored with novel oral anticoagul

151 n the ARISTOTLE trial, the rate of stroke or systemic embolism was reduced by apixaban compared with

152 All-cause stroke or systemic embolism was similar between both strategies (1

153 e TTR quartiles, hazard ratios for stroke or systemic embolism were 0.73 (95% confidence interval [CI

154 Rates of stroke or systemic embolism were 1.46% and 1.60%/y on dabigatran 1

155 ates for ischemic stroke and ischemic stroke/systemic embolism were explored.

156 The rates of stroke or systemic embolism were lower with dabigatran 150 mg and

157 Stroke and systemic embolism were not significantly different betwe

158 ninferior to warfarin in reducing stroke and systemic embolism, whether patients received antiplatele

159 absolute reduction in the rate of stroke and systemic embolism with apixaban versus warfarin was 0.77

160 GS: Apixaban significantly reduced stroke or systemic embolism with no evidence of a differential eff

161 . was noninferior to warfarin for stroke and systemic embolism without a difference in major bleeding

162 te 150 mg B.I.D. reduced the rates of stroke/systemic embolism without any difference in major bleedi